key: cord-0948472-opuqj9tl
authors: Noble, Johan; Langello, Antoine; Bouchut, William; Lupo, Julien; Lombardo, Dorothee; Rostaing, Lionel
title: Immune Response Post–SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept
date: 2021-08-11
journal: Transplantation
DOI: 10.1097/tp.0000000000003923
sha: 42de81b8409e37f82416be11df0314c5bf07e969
doc_id: 948472
cord_uid: opuqj9tl

nan

T he prevalence of seroconversion postvaccination to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is weaker in recipients of a solid-organ transplant compared with healthy individuals. The impact of different immunosuppressive therapies on the immunologic response after SARS-CoV-2 mRNA vaccines in kidney transplant recipients (KTx) is still ill-defined.

We assessed the specific humoral immunity response after SARS-CoV-2 mRNA vaccination in KTx receiving belatacept compared to KTx receiving tacrolimus.

Between February 2011 and April 2021, we included patients who had received consecutive KTx (at least 1-y posttransplantation) from our outpatient clinic and had received 2 doses of SARS-CoV-2 mRNA vaccine (BNT162b2 or Moderna COVID-19). Maintenance immunosuppression was based on either belatacept (every 4 wk) or tacrolimus, in addition to mycophenolic acid. At the time of the first vaccination, patients had a negative SARS-CoV-2 serology. For those receiving belatacept, the SARS-CoV-2 mRNA vaccination was performed at day 21 post-belatacept infusion (to reduce impact on immunogenicity). Blood samples were collected at the time of the first vaccination, 1 mo after the first, the second, and the third vaccination. Humoral immune response was assessed using an enzyme immunoassay against the S1 domain of the SARS-CoV-2 spike protein (Wantai Biological Pharmacy Enterprise Co., Beijing, China).

Fifty-seven patients were recruited: mean age was 62 ± 13 y. Immunosuppression was belatacept for 41 patients (72%) and tacrolimus for 16 patients (28%). Eighteen (31.5%) patients were female. Mean time from kidney transplantation was 122 ± 81 mo in the belatacept group and 174 ± 346 mo in the tacrolimus groups (P = 0.56).

Overall, 21 patients (36%) had a positive immune response post-SARS-CoV-2 vaccination (after the third dose). Of these, after the second dose, 7 (17%) belatacepttreated patients and 9 (56%) tacrolimus-treated patients were tested positive for anti-SARS-CoV-2 antibodies (P = 0.003). After the third vaccination, 20 belatacept patients were assessed: 4 patients were positive (20%). Of these, 1 was positive after the second dose, and 3 were negative. Two positive patients after the second dose of vaccine have lost their immunity after the third dose.

The anti-SARS-CoV-2 antibody titer increased significantly with the number of vaccinations (Figure 1 ), that is, 1.1 ± 4.7 after the first, 2.2 ± 5.7 after the second, and 3.3 ± 8 after the third SARS-CoV-2 mRNA vaccination.

The immune response to SARS-CoV-2 vaccination is lower in KTx recipients compared with healthy populations. 1 Herein, we confirm a low immune response (36%) after SARS-CoV-2 vaccination in KTx. In addition, KTx receiving belatacept had a significantly lower antibody response versus tacrolimus.

This trend was also found by Chavarot et al (2021) , who reported an antibody positivity of 5.7% in KTx receiving belatacept. 2 However, in that study, the SARS-CoV-2 vaccination was given at the same time as belatacept infusion, which possibly minimized vaccine immunogenicity. Ou et al (2021) reported on 609 KTx. Of these, 19 had received belatacept-based immunosuppression, but only 5% of these patients had anti-SARS-CoV-2 antibodies. 3 In our study, all patients received a vaccination at 21 d after belatacept infusion. This may explain the improved response to vaccination (ie, 17%) after the second vaccination. The serological Wantai assay is correlated to virus-neutralizing antibodies and is one with the higher sensitivity, which means that our results are not underestimated. 4, 5 In conclusion, belatacept significantly reduced the immune response to SARS-CoV-2 mRNA vaccination; however, delaying SARS-CoV-2 vaccination until 21 d after a belatacept infusion may improve immunogenicity. 

Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients

Poor Anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept

Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept

Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity, and association with virus neutralization test

Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories